BioSpace News Archive

Royal Philips, a global leader in health technology, announced that Willem Appelo will join Philips’ Executive Committee, effective July 18, 2022, and succeed Sophie Bechu as Chief Operations Officer per October 1, 2022.

Veru Inc. announced that is has submitted an emergency use authorization application to the U.S. Food and Drug Administration for its sabizabulin oral 9mg treatment of moderate to severe hospitalized COVID-19 patients at high risk for developing Acute Respiratory Distress Syndrome.

ViewRay, Inc. announced that Shin-Matsudo Central General Hospital has purchased a MRIdian MRI-guided radiation therapy system for installation at Shin-Matsudo Accuracy Radiation Therapy Center in Japan.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has appointed Simon Campion as executive vice president (EVP) and president of the Medical segment for BD, effective July 1, 2022.

Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc. (Nasdaq: EDIT, “Editas Medicine”), a leading genome editing company, today announced that the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta Treatment for cancer.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, California.

June 7, 2022 11:05 UTC In Vivo Preclinical Data Expected to Enable Three New IND Applications to Evaluate Company’s Gamma Delta T cell Product Candidates Procel™, Isocel™, and Deltacel™.

Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCD) today announced that it has entered into an amended and restated promissory note (the “ A&R Note ”) covering the up-front fee owed to former Serenity Pharmaceuticals LLC (“ Serenity ”) securityholders.

Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in person in a fireside chat at the annual JMP Securities Life Sciences Conference, which is being held at the Lotte New York Palace on June 15-16, 2022.